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Background: Antiretroviral therapy (ART) initiation in eligible HIV-infected pregnant women is an important
intervention to promote maternal and child health. Increasing the duration of ART received before delivery plays a
major role in preventing vertical HIV transmission, but pregnant women across Africa experience significant delays
in starting ART, partly due the perceived need to deliver ART counseling and patient education before ART
initiation. We examined whether delaying ART to provide pre-ART counseling was associated with improved
outcomes among HIV-infected women in Cape Town, South Africa.
Methods: We undertook a retrospective cohort study of 490 HIV-infected pregnant women referred to initiate
treatment at an urban ART clinic. At this clinic all patients including pregnant women are screened by a clinician
and then undergo three sessions of counseling and patient education prior to starting treatment, commonly
introducing delays of 2–4 weeks before ART initiation. Data on viral suppression and retention in care after ART
initiation were taken from routine clinic records.
Results: A total of 382 women initiated ART before delivery (78%); ART initiation before delivery was associated
with earlier gestational age at presentation to the ART service (p < 0.001). The median delay between screening and
ART initiation was 21 days (IQR, 14–29 days). Overall, 84.7%, 79.6% and 75.0% of women who were pregnant at the
time of ART initiation were retained in care at 4, 8 and 12 months after ART initiation, respectively. Among those
retained, 91% were virally suppressed at each follow-up visit. However the delay from screening to ART initiation
was not associated with retention in care and/or viral suppression throughout the first year on ART in unadjusted
or adjusted analyses.
Conclusions: A substantial proportion of eligible pregnant women referred for ART do not begin treatment before
delivery in this setting. Among women who do initiate ART, delaying initiation for patient preparation is not
associated with improved maternal outcomes. Given the need to maximize the duration of ART before delivery for
prevention of mother-to-child HIV transmission, there is an urgent need for new strategies to help expedite ART
initiation in eligible pregnant women.
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There were an estimated 12 million HIV-infected
women of reproductive age living in sub-Saharan Africa
during 2011, and 3.3 million in South Africa (SA) alone
[1]. In SA, the high national antenatal HIV seropreva-
lence (30%) means that a large number of pregnant
women require services to prevent the mother-to-child
transmission (PMTCT) of HIV infection [2]. Because
most perinatal HIV transmission takes place in women
with advanced HIV disease who are eligible for lifelong
antiretroviral therapy (ART) [3], ART initiation in preg-
nancy is a critical intervention both for PMTCT and for
the long-term health of mothers [4]. In this context, in-
creasing the time on ART before delivery contributes to
reductions in viraemia and decreases the risk of HIV
transmission in utero, during labour and delivery, and
postpartum when breastfeeding [5,6]. Several studies
have demonstrated that a one-week increase in the dur-
ation of ART received antenatally is associated with an
approximately 10% decrease in the risk of mother-to-
child transmission of HIV [7-9], making rapid ART initi-
ation in eligible pregnant women an important goal for
effective PMTCT services [10].
Despite the importance of rapid ART initiation for
PMTCT, across sub-Saharan Africa most pregnant
women face significant delays to starting ART [11]. Eli-
gible pregnant women are typically referred to general
adult ART clinics for treatment [12]. Once at ART
clinics, pregnant women enter a standardized system of
assessment and patient education that can delay ART
initiation by several weeks. In most settings, the systems
for adult ART initiation are focused on the needs of the
general adult population of non-pregnant women and
men, as pregnant women comprise only a small fraction
of new patients. [4,13] In the general population of non-
pregnant adults, systemic delays in ART initiation are
routinely used to allow time for patient education and
psychosocial preparation before treatment [14], based on
the idea that patient preparation before initiation may
improve retention in care and treatment adherence over
time [15-17], although evidence for this is lacking [18].
Systems that introduce delays in ART initiation for pa-
tient preparation before beginning treatment may have
important potential benefits for some adults. Yet in the
context of pregnancy, such delays can contribute to
increased risk of mother-to-child transmission of HIV.
Thus there is a potential risk-benefit balance to delaying
ART initiation in pregnancy: delays in ART initiation
may be useful to ensure adequate patient preparation (in
order to improve retention and adherence on treatment)
but also reduce the duration of ART received before de-
livery (and thus contribute to the vertical transmission of
HIV by delaying viral suppression). There are few data
to inform this risk-benefit assessment however. Inparticular, there are few studies of whether delayed ART
initiation for patient preparation improves patient out-
comes, including in the context of pregnancy where
delaying ART initiation may contribute to HIV transmis-
sion risk. To address this, we examined the impact of sys-
temic delays in ART initiation in eligible pregnant
women on treatment outcomes in Cape Town, South
Africa.
Methods
We undertook a retrospective cohort study of HIV-
infected women initiating ART in the community of
Gugulethu, where the antenatal seroprevalence in
2011 was more than 25%. The ART clinic serving
Gugulethu has been in operation since 2003 and
more than 9000 patients have been seen within the ser-
vice [19,20].
ART service
In Gugulethu, pregnant women who are identified as
ART-eligible according to immunological (CD4 cell
count <200 cells/μL until 2008, <250 cells/μL from 2008
to 2010, and <350 cells/μL since 2010) and/or clinical
criteria (WHO stage IV disease) at the nearby antenatal
clinic are referred for ART. Pregnant women are rou-
tinely initiated on zidovudine prophylaxis at the ante-
natal clinic, and continue this throughout the screening
period until ART initiation. At the ART clinic all
patients, including pregnant women, undergo three ses-
sions of counseling and ART education prior to starting
treatment. This often introduces a systemic delay of two
to four weeks into the process of ART initiation, al-
though individual clinicians can reduce this pre-ART
screening period. All patients, including women initiat-
ing ART during pregnancy, receive care free of charge
and are started on a regimen of 2 nucleoside reverse
transcriptase inhibitors and a non-nucleoside reverse
transcriptase inhibitor. Patients are followed-up at
monthly intervals for the first 4 months on ART, then 4-
monthly for the first 12 months on treatment. Immuno-
logical and virologic assessments are conducted at 4, 8
and 12 months on ART.
Data collection
We abstracted data from patient records for the 490
pregnant women who attended ART services in Gugu-
lethu between 2003 and 2010. We included data on:
demographic characteristics; the obstetric and clinical
history of women as recorded in patient records; dates
of clinic visits (including initial screening, ART initi-
ation, and subsequent follow-up visits); reasons for
delays in ART initiation; clinical information on staging
and opportunistic infections; and results of CD4 cell
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Figure 1 Plot of gestation at first screening visit at
antiretroviral therapy (ART) clinic (x-axis) among 408 pregnant
women screened for ART, with number of women who did and
did not start ART before delivery, as well as smoothed
probability of ART initiation before delivery. Smoothed
probabilities are from locally weighted scatterplot smoothing
(bandwidth, 0.8).
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Human Research Ethics Committee of the University of
Cape Town.
Analysis
Data were analyzed using Stata Version 11.0 (Stata Cor-
poration, College Station, USA). The principle exposure
of interest was the delay in days from women’s first
screening visit at the ART clinic to the date of ART initi-
ation; this was analysed as a continuous variable and
categorized into <14, 14–20, 21–34 and ≥35 days. We
examined other cutpoints, including a binary schema,
but this did not change the results substantively. The
principle outcomes of interest were retention in care and
virological suppression during the first 12 months on
treatment. Loss to follow-up (ie, failure to be retained in
care) was defined as having 60 days elapsed since the last
scheduled visit. Viral suppression was defined as <1000
copies/mL at any visit. Data were summarized using pro-
portions or medians with interquartile ranges (IQR). Bi-
variate analyses used rank-sum and Kruskall-Wallis tests
(for continuous variables) and Fisher’s exact tests (for
categorical variables); all statistical tests are 2-sided at
alpha = 0.05. Scatterplots with linear or locally-weighted
scatterplot smothing lines were used to graphically por-
tray the association between key variables. We examined
the association between delays to ART initiation and
women’s subsequent retention in care and viral suppres-
sion during the first 12 months after ART initiation using
log-linked regression models with robust standard errors.
In the model building process, we examined a range of
potential variables of interest, including calendar year
and baseline demographic, clinical and laboratory mea-
sures; variables were retained in the analysis if they were
the a priori exposures of interest (gestational age at
screening and delay from screening to ART initiation), if
they were independently associated with the outcome of
interest, or if their inclusion changed other associations
in the model appreciably. Model fit was examined using
likelihood ratio testing as well as Akaike’s Information
Criterion. The model results are presented as risk ratios
(RR) with 95% confidence intervals (CI).
Results
Of the 490 ART-eligible pregnant women who were seen
at the Gugulethu ART clinic, the median age was
27 years (IQR, 24–31) and the median gestational age
was 28 weeks (IQR, 24–32) at the time of the screening
visit. The nadir CD4 cell count at screening increased
from 125 cells/uL in 2004 to 205 cells/uL in 2010
(p < 0.001). A total of 108 women (22%) did not initiate
ART before delivery; women who did not start treatment
before delivery presented to the ART clinic at a signifi-
cantly later gestational age compared to women who didinitiate before delivery (median gestation age, 31 vs
27 weeks, respectively, p < 0.001; Figure 1). There was no
difference in women’s age, nadir CD4 cell count or base-
line viral load comparing those who were initiated dur-
ing pregnancy and those who were not (p > 0.2 for all
associations).
Table 1 describes the demographic, obstetric and clinic
characteristics of the 382 women who started ART dur-
ing pregnancy. In this group, the median nadir CD4 cell
count was 142 cells/μL (IQR, 96–186) and the median
log viral load was 4.4 log10 copies/mL (IQR, 3.7-4.8). Al-
most three-quarters of women presented to the ART
clinic after 24 weeks’ gestation, and 13% (50) presented
after 32 weeks’ gestation.
The median delay between screening and ART initi-
ation was 21 days (IQR, 14–29 days; range: 2–105 days),
with 54 women (14%) starting ART less than 2 weeks
after the date of screening and 111 women (29%) start-
ing ART 28 or more days after screening. The most
commonly noted reasons for delays to ART initiation of
more than 28 days were patients’ late attendance or
missed ART clinic visits (cited in 42% of instances,
n = 87) or women’s failure to complete patient education
sessions and/or a home visit (n = 65, 31%) (of 172
patients with explanations for the delay to ART initi-
ation; more than one reason for delay was possible). A
total of 19 women (11%) were delayed due to medical
concerns, primarily suspicion of tuberculosis.
There was a strong correlation between increased ges-
tation at first screening and decreased delay between
screening and ART initiation: 40% of women screened
after 32 weeks’ gestation started ART in less than








Delay from screening to ART initiation during antenatal period p-value
<14 days 14-20 days 21-27 days 28-34 days 35+ days
Number of patients 108 382 54 136 61 66 65 –
Median age (IQR) 26 (23–31) 27 (24–31) 29 (24–32) 27 (24–31) 28 (25–32) 27 (25–31) 27 (25–31) 0.965
Median gestation (IQR) 31 (27–34) 27 (23–31) 32 (28–34) 28 (26–32) 27 (23–30) 24 (20–28) 21 (17–25) <0.001
<24 weeks 12 (12) 104 (27) 3 (6) 14 (10) 16 (26) 30 (45) 41 (63) <0.001
24-28 weeks 25 (24) 134 (35) 12 (22) 57 (42) 26 (43) 21 (32) 18 (28)
29-32 weeks 33 (31) 94 (25) 19 (35) 40 (29) 14 (23) 15 (23) 6 (9)
>32 weeks 34 (33) 50 (13) 20 (37) 25 (18) 5 (8) 0 0
WHO stage: I 67 (62) 206 (55) 25 (48) 83 (62) 38 (62) 34 (52) 26 (40) 0.003
II 17 (16) 69 (18) 7 (13) 29 (22) 10 (16) 13 (20) 10 (15)
III 22 (20) 90 (24) 17 (33) 18 (13) 13 (21) 15 (23) 27 (42)
IV 2 (2) 13 (3) 3 (6) 4 (3) 0 4 (6) 2 (3)
Median CD4
cell count (IQR) *
120 (65–166) 142 (96–186) 139 (85–187) 143 (96–186) 153 (112–210) 133 (104–170) 134 (94–172) 0.538
CD4 <100 cells/μl 9 (39) 99 (28) 19 (36) 38 (29) 11 (19) 15 (24) 16 (29)
Median HIV
Viral load (IQR) *
4.9 (4.6-4.9) 4.3 (3.7-4.8) 4.2 (3.4-4.8) 4.2 (3.8-4.8) 4.4 (3.9-4.9) 4.5 (3.9-4.9) 4.6 (4.1-4.8) 0.211
>5 log10 copies/mL 3 (15) 55 (15) 9 (17) 17 (13) 8 (14) 13 (21) 8 (15)
* For the 108 women not starting ART, CD4 data were available on 23 patients (21%) and viral load data were available on 22 patients (20%); for the 382 women
starting ART, CD4 data were available on 357 patients (93%) and viral load data were available on 358 patients (94%).
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before 24 weeks’ gestation (p < 0.001; Figure 2). The
median gestation at ART initiation was 30 weeks (IQR,
23–31) and the median duration of ART received be-
fore delivery was 8 weeks (IQR, 5–13 weeks). Increas-
ing duration of ART before delivery was associated
with shorter delays between screening and ART initi-
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Figure 2 Plot of gestation at first screening visit in ART clinic
(x-axis) and delay between screening and ART initiation before
delivery (y-axis), among 382 pregnant women initiating ART.
Points are individual observations, with best-fit line summarizing the
overall association.Figure 3 shows the levels of patient retention and viral
suppression at months 4, 8 and 12 following ART initi-
ation according to the delay between screening and ART
initiation. Overall, 84.7%, 79.6% and 75.0% of women
who were pregnant at the time of ART initiation were
retained in care at 4, 8 and 12 months after ART initi-
ation, respectively (there were 11 deaths during the first
12 months on ART, with no differences by category of
delay from screening to ART initiation). Among women
retained, 91% were virally suppressed to <1000 copies/mL
at each of these visits.
In regression modeling (Table 2), the delay from
screening to ART initiation was not associated with
the combined endpoint of retention in care and viral
suppression during the first year on ART in unadjusted
or adjusted analyses. After adjusting for women’s age
and gestational age at screening, women initiating ART
14–20, 21–27, 28–34 and more than 35 days after
screening were not significantly more or less likely to
be retained in care and virally suppressed, compared to
women starting ART less than 14 days after screening
(RR: 0.95, 0.97, 1.07 and 0.89, respectively). This find-
ing did not change when the delay variable was cate-
gorized as a binary variable around the median of
21 days (not shown). In the final model, increasing
participant age was the only factor associated with in-
creasing probability of retention in care and viral sup-
pression over time.
Figure 3 Levels of (A) retention in care and (B) viral suppression at 4, 8 and 12 months after antiretroviral therapy (ART) initiation
among women who were pregnant at the time of ART initiation, according to the delay period from screening to ART initiation.
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This analysis shows that pregnant women who are re-
ferred to an adult ART service for treatment initiation
may face significant delays in initiating ART. As a result
of these delays, a sizable proportion of women in this
setting did not initiate ART before delivery. Among
women who did initiate ART during the antenatal
period, there was substantial variability in the delays
from women’s first screening at the ART clinic to start-
ing therapy, but the duration of systemic delays before
ART initiation was not associated with improved patientTable 2 Unadjusted (panel A) and adjusted (panel B) regressi




<25 years 1.0 (ref)
25-30 years 1.09 0.95-1.27
>30 years 1.19 1.03-1.39
Gestation at screening
<24 weeks 1.0 (ref)
24-28 weeks 0.99 0.86-1.13
29-32 weeks 0.97 0.84-1.13
>32 weeks 0.97 0.80-1.18
Delay from screening to ART initiation
<14 days 1.0 (ref)
14-20 days 0.95 0.80-1.12
21-27 days 0.97 0.80-1.18
28-34 days 1.07 0.90-1.26
>35 days 0.89 0.72-1.03
Associations are shown as risk ratios (RR) with 95% confidence intervals (CI).
* Adjusted associations are adjusted for all covariates shown.outcomes on treatment. Given the urgency of ART initi-
ation in pregnancy to prevent vertical HIV transmission,
these data have important implications for the design of
ART services for eligible pregnant women.
The median delay from screening at the ART clinic to
ART initiation was 21 days (IQR, 14–29). When
coupled with a median gestation at screening of
27 weeks, most women received 8 weeks or less of
therapy prior to delivery. While the duration of ART
required in pregnancy to achieve viral suppression is
influenced by pre-ART viraemia and the antiretroviralon models predicting the combined endpoint of retention
RT
(B) Adjusted associations *
p-value RR 95% CI p-value
1.0 (ref)
0.212 1.10 0.95-1.28 0.192
0.019 1.20 1.03-1.39 0.018
1.0 (ref)
0.875 0.95 0.81-1.10 0.476
0.722 0.93 0.78-1.10 0.391
0.768 0.92 0.73-1.16 0.466
1.0 (ref)
0.549 0.96 0.81-1.14 0.655
0.777 0.95 0.77-1.17 0.654
0.448 1.04 0.85-1.26 0.708
0.264 0.86 0.67-1.09 0.206
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of therapy is required to achieve viral suppression in
most women and in turn minimize the risk of vertical
HIV transmission [9,21]. Following from this, while we
did not measure viral suppression at delivery or infant
HIV outcomes as part of this routine service, it is likely
that a proportion of the women had significant viraemia
and, therefore, were at increased risk of HIV transmis-
sion at the time of delivery [21].
Here we analyzed the delay from screening to initi-
ation of ART as a proxy for the time available for patient
preparation before starting therapy. This delay may in-
fluence patient preparation in two related ways. First,
increased time before starting ART provides time for
formal patient counseling sessions, as group counseling
sessions take place at regularly scheduled intervals each
week at the ART clinic. Second, it is possible that some
period of time before ART initiation may be useful to
help some patients adjust individually to the need to
start lifelong therapy, as ART initiation is accompanied
by psychosocial stressors related to HIV stigma and dis-
closure, and may be particularly complex in the context
of pregnancy [22]. It is important to note that the delay
variable used here cannot distinguish these two con-
structs, and we do not have measures of the number of
counseling sessions attended nor any markers of
patients’ perceived readiness to initiate therapy. None-
theless, the overall delay between screening and ART
initiation is a useful indirect measure of both phenom-
ena in combination.
Although delays from ART screening to initiation lim-
ited the total duration of ART received before delivery,
these data suggest that there was no apparent benefit to
these delays on maternal outcomes. Levels of retention
in care appeared relatively low but viral suppression was
relatively high among those retained. However neither of
these outcomes varied according to the length of delay
from screening to ART initiation. This finding is in
keeping with the general literature on patient prepar-
ation before ART initiation: while there are hypotheses
that delaying ART initiation for patient preparation con-
tributes to improved outcomes [15,16], there are few
empirical data that support these hypotheses [18,23]. In
the absence of such an association, the benefits of delay-
ing ART initiation in pregnancy for adherence prepar-
ation and counseling are unclear.
This is one of the first studies to investigate the impact
of systemic delays before ART initiation during preg-
nancy on ART outcomes. There are other populations of
HIV-infected individuals in which systemic delays to
ART initiation contribute to avoidable morbidity and
mortality, including adults with advanced immunosup-
pression [24], individuals with tuberculosis [25], and
perinatally-infected infants [26] (although there areother clinical situations in which rapid ART initiation
may lead to clinical deterioration [27]). In each of these
groups, observational evidence followed by definitive
randomized controlled trials has shown that the risks
associated with delayed ART initiation are outweighed
by the benefits of expedited therapy. Timing of ART ini-
tiation in pregnancy is quite different from these exam-
ples, however: HIV-infected pregnant women are usually
relatively healthy; the short-term benefits of rapid ART
initiation are primarily in reducing transmission risk;
and the principle threats to the retention of pregnant
women on ART may be loss to follow-up and inad-
equate adherence rather than morbidity and mortality.
In this light, while these results could be interpreted to
support a ‘test-and-treat’ approach to ART in pregnancy
[28,29] - where all HIV-infected pregnant women are
initiated on ART immediately, regardless of clinical or
immunological status – these findings should be inter-
preted with care. In particular, the data come a group of
women with relatively low CD4 cell counts (median, 142
cells/μL) attending a single, relatively large ART clinic in
South Africa. The results may not be generalizable to
other geographic settings and populations of pregnant
women, and there is a clear need for additional investi-
gation of any ‘test-and-treat’ approach to manage HIV in
pregnancy.
The findings reported here should be viewed in light
of several important limitations. Because information
was taken from a retrospective review of patient records,
we do not have available several measures of interest, in
particular data on deliveries, neonatal health, and infant
HIV testing outcomes. In addition, women commonly
arrived at the ART clinic having taken zidovudine
PMTCT prophylaxis for several weeks, clouding the in-
terpretation of ‘baseline’ pre-ART viral loads. After ART
initiation, viral load testing was conducted according to
women’s duration on ART and there was not viral load
testing at the time of delivery; thus we have little insight
into the overall proportion of women who achieved viral
suppression by delivery. Moreover we do not have
detailed information on the precise reasons why ART
initiation was expedited in some women and delayed in
others: if the reasons underlying the length of this delay
are associated with women’s outcomes on ART, this may
represent an important, unmeasured confounding factor.
Such confounding by indication is commonplace
throughout clinical research [30], including studies of
the timing of ART initiation [31], and can only be com-
prehensively addressed through randomized studies [32].
Despite these limitations, this study has important
implications for services to initiate ART in eligible preg-
nant women. There are well-established risks associated
with delaying ART initiation in pregnancy, in terms of
vertical transmission of HIV [10] as well as maternal
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associated with delayed ART initiation has been sug-
gested in terms of improved maternal outcomes on treat-
ment (due to increased time for patient preparation),
these data suggest no such benefit. In turn, the need to
expedite ART in pregnancy is likely to outweigh the pu-
tative benefits of delaying therapy for patient education.
Although patient education and counseling is a critical
part of ART initiation, the usefulness of delaying ART
until after patient education and counseling is complete
is unclear. This points in turn to the need for strategies
to initiate ART as quickly as possible in the context of
pregnancy, but few models for this exist, and any inter-
vention strategy must address the multiple factors that
combine to delay ART initiation in pregnancy [34].
Conclusions
In summary, these data show that that ART-eligible
pregnant women experience significant delays before be-
ginning treatment, and that such delays are not asso-
ciated with improved maternal health outcomes. Given
the need to maximize the duration of ART before deliv-
ery, there is an urgent need for new strategies to help
expedite ART initiation in pregnancy to promote both
maternal and child health.
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